Integra LifeSciences (NASDAQ:IART – Get Free Report) posted its quarterly earnings data on Monday. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.02, Briefing.com reports. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.25%. The company’s revenue was down .4% compared to the same quarter last year. During the same period last year, the firm posted $0.76 earnings per share.
Integra LifeSciences Price Performance
IART stock opened at $26.70 on Thursday. The business’s fifty day moving average price is $18.90 and its 200 day moving average price is $24.40. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a market capitalization of $2.07 billion, a PE ratio of -296.67, a P/E/G ratio of 0.82 and a beta of 1.08. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17.
Analysts Set New Price Targets
Several research firms recently issued reports on IART. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America dropped their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. JMP Securities cut their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a report on Tuesday, July 30th. Finally, Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $27.25.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
See Also
- Five stocks we like better than Integra LifeSciences
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 2 Reasons To Like Coinbase After The Election, 1 to Still Avoid
- Find and Profitably Trade Stocks at 52-Week Lows
- Hunting for High-Yield Bargains? 2 REITs to Consider
- Stock Sentiment Analysis: How it Works
- Fiserv Is Up 50% This Year and Can Go Another 50% Higher
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
